Philipp du Cros Selected Research

Philipp du Cros Research Topics

6	Tuberculosis (Tuberculoses) 12/2023 - 01/2014
5	Infections 01/2024 - 02/2004
4	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 06/2022 - 10/2017
2	Pulmonary Tuberculosis 12/2022 - 06/2022
1	Pericarditis 04/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2017
1	Optic Nerve Diseases (Optic Neuropathy) 12/2017
1	Extensively Drug-Resistant Tuberculosis 01/2016
1	Buruli Ulcer 09/2013
1	Coinfection 07/2012
1	Fibrosis (Cirrhosis) 07/2012
1	Hepatitis 07/2012
1	Hydrocephalus (Hydrocephaly) 07/2006
1	Central Nervous System Infections (Central Nervous System Infection) 07/2006
1	Endocarditis 02/2004

5	Rifampin (Rifampicin)FDA LinkGeneric 11/2023 - 02/2004
4	Linezolid (Zyvox)FDA Link 12/2017 - 02/2004
3	bedaquiline (R207910)IBA 06/2022 - 01/2014
1	Interferon-gamma (Interferon, gamma)IBA 01/2024
1	Tuberculin (PPD)IBA 01/2024
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 12/2023
1	pretomanidIBA 06/2022
1	SteroidsIBA 04/2020
1	FluoroquinolonesIBA 12/2017
1	Indicators and Reagents (Reagents)IBA 07/2015
1	OPC-67683IBA 01/2014
1	Moxifloxacin (Avelox)FDA Link 09/2013
1	RNA (Ribonucleic Acid)IBA 07/2012
1	Stavudine (Zerit)FDA LinkGeneric 07/2012
1	Vancomycin FDA LinkGeneric 02/2004
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2004
1	Fusidic Acid (Fucithalmic)IBA 02/2004

4	Therapeutics 06/2022 - 02/2004
1	Injections 12/2017
1	Off-Label Use 10/2017
1	Highly Active Antiretroviral Therapy (HAART) 07/2012
1	Ventriculoperitoneal Shunt 07/2006